Graig Suvannavejh
Stock Analyst at Mizuho
(2.21)
# 2,515
Out of 4,829 analysts
142
Total ratings
42.06%
Success rate
-6.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Maintains: Neutral | $38 → $33 | $28.40 | +16.20% | 8 | Apr 7, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $3 → $7 | $4.61 | +51.84% | 6 | Apr 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $212 → $216 | $107.76 | +100.45% | 21 | Mar 27, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $42 → $44 | $34.06 | +29.20% | 17 | Mar 18, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Outperform | $3 → $1.5 | $0.29 | +412.65% | 2 | Nov 27, 2024 | |
| AUTL Autolus Therapeutics | Upgrades: Buy | $7 → $7.6 | $1.32 | +475.76% | 1 | Nov 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $39 → $38 | $17.30 | +119.65% | 6 | Oct 24, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterates: Outperform | $74 | $6.45 | +1,047.29% | 1 | Sep 20, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | $5 → $0.5 | $0.25 | +96.62% | 3 | Sep 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $44 → $49 | $65.87 | -25.61% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $17.42 | +187.03% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $0.66 | +2,917.05% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $82 | $65.08 | +26.00% | 6 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $4.26 | +276.03% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $30 | $5.81 | +416.35% | 4 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $22 | $2.81 | +682.92% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $8 | $1.14 | +601.75% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 | $4.43 | -20.99% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $3.04 | +228.95% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $1.17 | +669.23% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $1.53 | +4,083.01% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $6.90 | -85.51% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $2.46 | +509.76% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $57.38 | -39.00% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $3.77 | +112.20% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $31.70 | +79.84% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $33.64 | -85.14% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $6.47 | +425.50% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $3.50 | +700.00% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $14.58 | +112.62% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $0.15 | +12,457.83% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $2.44 | +94.78% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $13.53 | +166.08% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $25.31 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.80 | +4,512.89% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $97.78 | +30.91% | 1 | Sep 14, 2020 |
Immunocore Holdings
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $28.40
Upside: +16.20%
Amylyx Pharmaceuticals
Apr 7, 2025
Upgrades: Outperform
Price Target: $3 → $7
Current: $4.61
Upside: +51.84%
Axsome Therapeutics
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $107.76
Upside: +100.45%
Harmony Biosciences Holdings
Mar 18, 2025
Maintains: Outperform
Price Target: $42 → $44
Current: $34.06
Upside: +29.20%
Adaptimmune Therapeutics
Nov 27, 2024
Maintains: Outperform
Price Target: $3 → $1.5
Current: $0.29
Upside: +412.65%
Autolus Therapeutics
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.32
Upside: +475.76%
Apellis Pharmaceuticals
Oct 24, 2024
Maintains: Neutral
Price Target: $39 → $38
Current: $17.30
Upside: +119.65%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $6.45
Upside: +1,047.29%
Athira Pharma
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.25
Upside: +96.62%
Halozyme Therapeutics
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $65.87
Upside: -25.61%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $17.42
Upside: +187.03%
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $0.66
Upside: +2,917.05%
Jun 7, 2024
Maintains: Buy
Price Target: $36 → $82
Current: $65.08
Upside: +26.00%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $4.26
Upside: +276.03%
May 7, 2024
Maintains: Buy
Price Target: $39 → $30
Current: $5.81
Upside: +416.35%
Apr 29, 2024
Maintains: Buy
Price Target: $40 → $22
Current: $2.81
Upside: +682.92%
Apr 2, 2024
Maintains: Buy
Price Target: $20 → $8
Current: $1.14
Upside: +601.75%
Mar 27, 2024
Maintains: Neutral
Price Target: $3.5
Current: $4.43
Upside: -20.99%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $3.04
Upside: +228.95%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $1.17
Upside: +669.23%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $1.53
Upside: +4,083.01%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $6.90
Upside: -85.51%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $2.46
Upside: +509.76%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $57.38
Upside: -39.00%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $3.77
Upside: +112.20%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $31.70
Upside: +79.84%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $33.64
Upside: -85.14%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $6.47
Upside: +425.50%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $3.50
Upside: +700.00%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $14.58
Upside: +112.62%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $0.15
Upside: +12,457.83%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $2.44
Upside: +94.78%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $13.53
Upside: +166.08%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $25.31
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.80
Upside: +4,512.89%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $97.78
Upside: +30.91%